Biogen Inc
Biogen is a U.S.-based biopharmaceutical company built around therapies for serious neurological, immunological and rare diseases. Its commercial base includes multiple sclerosis medicines, spinal muscular atrophy treatment SPINRAZA, rare-disease drug SKYCLARYS, and ALS therapy QALSODY, alongside collaboration-driven exposure to Alzheimer’s and postpartum depression products. The company combines internal R&D with external partnerships, licensing and acquisitions to expand its pipeline and access new technologies. A meaningful part of the business also comes from biosimilars, contract manufacturing and royalty income tied to collaboration arrangements.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBranded medicines used to treat relapsing and progressive forms of MS, including legacy and newer products.
Treatments for SMA, Friedreich’s ataxia and ALS, plus related pipeline and launch products.
Biologic follow-on products commercialized in selected international markets through partners and distributors.
Manufacturing services, royalty income and other collaboration-related revenue streams.
Customers
Biogen sells primarily to wholesale and specialty distributors, specialty pharmacies, hospitals and pharmacies, which then resell to health care providers and patients. In the U.S., the company focuses its sales and marketing efforts on health care providers in private practice and major medical centers, reflecting the specialist nature of its therapies. Demand is driven by physicians treating chronic neurological and rare diseases, as well as payors and reimbursement systems that determine patient access. Collaboration revenue also comes from partners such as Eisai, Supernus, Samsung Bioepis and Roche/Genentech arrangements, which broaden the customer and counterparty base beyond direct drug sales.
Buy Biogen products in the U.S. and abroad and distribute them into specialty care channels where reimbursement and patient support are critical.
Prescribe and administer Biogen therapies for MS, SMA, ALS and rare diseases, making them central to product adoption.
Influence access, pricing and utilization through coverage decisions, prior authorization and reimbursement levels.
Eisai, Supernus, Samsung Bioepis and Roche-related partners contribute commercialization, royalties, manufacturing or profit-sharing revenue.
Hospitals, wholesalers and tender-based purchasers in Europe and other markets buy lower-cost biosimilars.
Strategy
Biogen’s strategy is to defend and refresh its neuroscience franchise while building growth in rare disease, specialized immunology and selected collaboration assets. The company is using external partnerships and acquisitions to broaden its pipeline, as shown by collaborations with Eisai and Supernus and the HI-Bio acquisition. It is also rationalizing costs through the Fit for Growth program, which is intended to improve operating efficiency while funding reinvestment in launches and development. Longer term, the company is relying on new product approvals, additional indications and manufacturing scale to offset MS erosion and biosimilar competition.
The legacy MS portfolio faces generic and biosimilar pressure, so growth depends on newer products and indications.
Cost savings help fund pipeline investment and protect margins as older products decline.
Biogen relies on partnerships and acquisitions to supplement internal R&D and speed access to assets.
Reliable supply is critical for specialty biologics and for supporting launches and collaboration batches.
Geography
Biogen is headquartered in the United States and generates a large share of product revenue there, with the remainder coming from rest-of-world markets. The company sells and distributes products through different channels by country, including wholesale distributors, specialty pharmacies, hospitals and third-party partners. It also operates and invests in manufacturing capacity outside the U.S., including a large biologics facility in Solothurn, Switzerland, which supports LEQEMBI and TYSABRI production. International exposure matters because biosimilar adoption, pricing actions, reimbursement and tendering vary materially by market and can quickly affect revenue mix.
Risks
Biogen faces direct erosion risk in its legacy MS franchise as generics, biosimilars and newer therapies reduce pricing and volume. Its biosimilar business is exposed to regulatory uncertainty, intellectual property disputes, tendering pressure and dependence on third-party manufacturers and partners. The company also depends heavily on reimbursement decisions, so coverage changes or pricing actions can quickly affect access and revenue. More broadly, biopharma development carries clinical trial failure risk, manufacturing complexity, and the possibility that competitors launch superior or lower-priced therapies before Biogen’s pipeline matures.
- Generic and biosimilar competition in MSImpact: HighLikelihood: High
Legacy products such as TECFIDERA and TYSABRI are already seeing demand and pricing pressure from lower-cost entrants.
Exposure: Multiple sclerosis portfolio
- Reimbursement and pricing pressureImpact: HighLikelihood: High
Specialty drugs depend on coverage and reimbursement, and pricing actions can reduce net revenue quickly.
Exposure: U.S. and international specialty markets
- Third-party manufacturing dependenceImpact: HighLikelihood: Medium
Biogen relies on external manufacturers for some biosimilars and collaboration products, which can constrain supply or quality.
Exposure: Biosimilars and partnered products
- Clinical development failureImpact: HighLikelihood: Medium
Pipeline value depends on successful trials, approvals and label expansion, which are inherently uncertain.
Exposure - Intellectual property and regulatory challengesImpact: MediumLikelihood: High
Biosimilars and biologics face patent disputes, regulatory hurdles and delayed launches that can impair commercialization.
Exposure: Biosimilars and pipeline assets
Accounting
Judgemental itemsSpecialty drug pricing and reimbursement create variable consideration that must be estimated and can materially affect net sales.
Impact: Net product revenue
LEQEMBI-related batches and other manufacturing work can shift between quarters based on production timing.
Impact: Quarterly revenue volatility
Biogen recognizes shared profits and royalty income from partners such as Samsung Bioepis, Eisai and Sage.
Impact: Other revenue and operating income
Fit for Growth severance and facility-related costs affect operating expense comparability.
Impact: Operating margin and cash flow
Tax exposures and acquisition-related milestones require accruals and can create cash outflows not tied to current sales.
Impact: Liabilities and earnings
Similar listed companies
Publicly listed companies with a comparable business focus.
Ionis Pharmaceuticals, Inc
IONS · Pharmaceutical Preparations
Ionis Pharmaceuticals is a U.S.-based biotechnology company focused on RNA-targeted medicines, using antisense chemistry to discover and develop therapies for serious diseases.
Compugen Ltd
CGEN · Biological Products, (No Diagnostic Substances)
Stoke Therapeutics, Inc.
STOK · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Arrowhead Pharmaceuticals, Inc
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026